Danielle Valletti, Assistant Editor

Carfilzomib may boost BCMA CAR T-cell therapy after relapse in multiple myeloma, guiding oncology pharmacists on safer immunotherapy sequencing.

The oral solution improves central diabetes insipidus dosing precision, helping pharmacy teams tailor therapy, counsel patients, and monitor hyponatremia.

Oncology pharmacists can advocate and communicate clearly to boost recognition, strengthen care teams, and improve cancer treatment outcomes.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

FDA clears oral Wegovy pills for weight loss, while Lemme Burn Gummies tout metabolic support; plus new thalassemia anemia drug and Lucentis biosimilar.

Oncology pharmacists can share advocacy tips, craft elevator pitches, and use virtual Capitol Hill days to boost patient access and cancer care.

Circulating tumor cell PD-L1 liquid biopsy guides PD-1 therapy in lung cancer, helping oncology pharmacists predict response and monitor disease in real time.

Experts discuss the importance of optimizing immunotherapy for advanced NSCLC, enhancing treatment selection and patient care.

Tagraxofusp monotherapy in myelofibrosis shows symptom relief with manageable toxicity, as pharmacists can monitor capillary leak syndrome and cytopenias.

Neurology CPAs let pharmacists speed multiple sclerosis therapy, order labs and meds, cut delays, boost adherence, and expand collaborative care.

FDA accepts Iberdomide new drug application for relapsed or refractory multiple myeloma; pharmacists prepare for oral anti-CD38 combos, MRD-driven care.

Expanded Medicaid coverage has been linked to access to early diagnosis, timely treatment, and continuity of care in breast cancer.

FDA approves difamilast (Adquey), a topical PDE4 inhibitor, expanding nonsteroidal options for mild to moderate atopic dermatitis in dermatology patients 2 years and older.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

WADA tracks GLP-1s like Ozempic, Wegovy, and Zepbound at the Olympics as pharmacists weigh muscle-loss risks and sports pharmacy guidance.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.

Explore emerging evidence on aspirin’s potential role in reducing cancer risk and improving survival.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

GDF15 can reshape prostate cancer prognosis and treatment; pharmacists track emerging biomarker panels and targeted therapies for metastatic disease.

Pharmacists can use collaborative practice agreements in neurology to manage multiple sclerosis medications, labs, and expand care beyond disease-modifying therapies.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

Oncology pharmacists use MammaPrint to target anthracyclines in high-risk breast cancer, sparing others cardiotoxicity and severe nausea.

RESTORE trial data show investigational elritercept improves myelofibrosis anemia and cytopenias, reduces transfusions, and guides pharmacists on monitoring with ruxolitinib.

DPYD Testing reshapes oncology dosing for 5‑FU/capecitabine to prevent toxicity and personalize chemotherapy.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

Embedded pharmacy experts in neurology strengthen multiple sclerosis care through education, therapy selection, lab monitoring, and collaborative practice agreements that close gaps.

Explore how pharmacists can support patients with pancreatic cancer taking atebimetinib as Immuneering leaders and oncologists discuss tolerability, education, and survival-focused phase 3 trial goals.